AI 检索
AI 阅读
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

A randomized, open-label study of the tolerability and efficacy of one or three daily doses of ivermectin plus diethylcarbamazine and albendazole (IDA) versus one dose of ivermectin plus albendazole (IA) for treatment of onchocerciasis.

Nicholas O Opoku,Felix Doe,Bettina Dubben,Nicole Fetcho,Kerstin Fischer,Peter U Fischer, Shelter Gordor,Charles W Goss,Michael E Gyasi,Achim Hoerauf,Augustine R Hong,Eric Kanza,Christopher L King, Ruth Laryea,Daphne Lew,Mahmood A Seidu,Gary J Weil

PLoS neglected tropical diseases（2023）

引用 0|浏览2
暂无评分
摘要
The study is registered at Cinicaltrials.gov under the number NCT04188301.
更多
查看译文
关键词
onchocerciasis,ivermectin,diethylcarbamazine,daily doses,albendazole,open-label
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要